Cognition Therapeutics' Phase 2 SHINE Study Results on CT1812 for Alzheimer's to be Presented at AAIC

Cognition Therapeutics Inc., a company focused on developing treatments for neurodegenerative diseases, has announced that its findings from the Phase 2 COG0201 "SHINE" study of CT1812 will be presented at the Alzheimer's Association’s International Conference in Philadelphia, from July 28 to August 1, 2024. These findings will be shared through various poster presentations.

The presentations include:
1. Clinical efficacy results from the COG0201 study, a randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of CT1812 in adults with mild-to-moderate Alzheimer’s disease.
2. An analysis of cerebrospinal fluid (CSF) phosphoproteomics biomarkers from the SHINE study, aiming to clarify the role of CT1812 in Alzheimer’s disease.
3. Topline CSF biomarker outcomes from the SHINE study for Alzheimer's patients.
4. Exploratory CSF proteomics biomarker outcomes to assess the effects of CT1812 in Alzheimer's patients.

Additionally, the company will have a booth (#731) in the Exhibit Hall, providing more details about its Alzheimer’s disease program and CT1812.

The SHINE study is a Phase 2 clinical trial involving approximately 144 patients with mild-to-moderate Alzheimer’s disease. These participants were randomly assigned to receive either a placebo or one of two doses of CT1812 (100 mg or 300 mg) taken daily over six months. Primary endpoints include safety, cognitive function as measured by the ADAS-Cog 11 scale, and biomarker evidence of disease modification. The study was funded by two grants from the National Institute on Aging, totaling around $30 million.

CT1812 is an experimental small molecule drug that crosses the blood-brain barrier and selectively binds to the sigma-2 receptor complex. Preclinical and clinical data indicate that this binding displaces toxic amyloid-beta (Aβ) oligomers. The sigma-2 receptor complex is involved in important cellular processes like membrane trafficking and autophagy, which are disrupted by toxic interactions with Aβ oligomers and oxidative stress. This disruption can lead to synaptic damage and cognitive impairment, key features in Alzheimer’s disease progression.

Recruitment is ongoing for the START study of CT1812 in early Alzheimer’s patients and the MAGNIFY study for geographic atrophy secondary to dry age-related macular degeneration. Enrollment has been completed for the SHIMMER study of CT1812 in patients with dementia with Lewy bodies and for the SHINE study.

Cognition Therapeutics, Inc. is dedicated to discovering and developing innovative small molecule therapeutics for age-related degenerative diseases of the central nervous system and retina. The company’s lead candidate, CT1812, is currently being tested in clinical programs for Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company believes that targeting the sigma-2 receptor with CT1812 offers a unique approach compared to other current treatments for degenerative diseases.